India, Jan. 29 -- Aethlon Medical Inc. (AEMD), a medical device company, announced on Wednesday, that it has reached a milestone in its Australian safety, feasibility, and dose-finding clinical trial of Hemopurifier.
The Aethlon Hemopurifier is an investigational medical device developed to filter out enveloped viruses and tumor-derived extracellular vesicles from the bloodstream. It is an extracorporeal device that works in conjunction with a blood pump.
Preclinical studies have shown that the Hemopurifier can reduce extracellular vesicles concentrations, which are linked to cancer spread and resistance to therapies.
The company noted that the first patient who was enrolled in the trial on October 29, 2024, at the Cancer Clinical Trials...